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ess: vega@xa2.so-net.nSummary Microscopic polyangiitis (MPA) is a systemic necrotizing vasculitis that
affects small vessels, resulting in a wide spectrum of organ involvement including
the lungs. However, there are little serological markers that predict its prognosis or
severity of pulmonary involvement. Vascular endothelial growth factor (VEGF) is an
angiogenic mediator, which has been reported to be elevated in systemic vasculitis.
In this study, we measured serum VEGF levels in 22 MPA patients with pulmonary
involvement. We also investigated VEGF expression in pulmonary cells using flow
cytometry analysis. We found that serum VEGF levels in MPA patients were
significantly higher than those in respiratory or urinary tract infection. The serum
VEGF levels decreased in parallel with the improvement of MPA symptoms. The
serum VEGF levels in MPA patients who died within 5 years were significantly higher
than those who survived more than 5 years. The sensitivity of VEGF levels to
distinguish MPA patient with poor prognosis from those with good prognosis was
90.9%, and specificity was 81.8% (cutoff value ¼ 802.5 pg/ml). The serum VEGF
levels showed significant positive correlation with the composite physiological index,
which indicates the severity of pulmonary lesion. In flow cytometry analysis, CD11b
positive bronchoalveolar lavage fluid cells expressed VEGF. Immunohistochemically,
alveolar macrophages, tissue infiltrating inflammatory cells and alveolar epithelial
cells stained positive for VEGF. Measurement of serum VEGF levels in MPA might
become one of the markers for prognosis and the severity of pulmonary involvement
in MPA. VEGF might contribute to the development of pulmonary lesion of MPA.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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VEGF in MPA 1725Introduction patients with urinary tract infection (male : femaleMicroscopic polyangiitis (MPA) is a rare systemic
disease that shows necrotizing vasculitis in small
vessels, resulting in a wide spectrum of organ
involvement including the lungs.1 The etiology of
this condition is unknown and the MPA patient
typically presents with renal dysfunction or pul-
monary hemorrhage2 and its 5-year survival rate is
reported as 45%.3 In addition, several studies
described that MPA reveals a variety of pulmonary
findings.4–6 However, there has been little serolo-
gical marker for its prognosis or severity of
pulmonary involvement.
Vascular endothelial growth factor (VEGF), a
homodimeric, heparin-binding glycoprotein of
34–42 KD, is one of the major mediators of
angiogenesis and vascular permeability.7,8 VEGFs
and their receptors have been implicated in the
regulation of vascular permeability in many organ
systems, including the lung.9 There has been
several reports describing the importance of VEGF
in systemic vasculitis, such as Wegener’s granulo-
matosis,10 Giant cell arteritis11 and Kawasaki
disease.12 In pulmonary inflammatory disorders,
VEGF has been reported to play an important role
in the development of their lesion via its capacity
to increase vascular permeability.9,13–15 In this
study, we hypothesized that serum VEGF level
might be useful to predict the prognosis of MPA
and the severity of pulmonary involvement in MPA
and investigated 22MPA patients who have pulmon-
ary involvement. We found that serum VEGF level
of MPA patients had significant positive correlation
with the severity of pulmonary lesion and activated
pulmonary neutrophils expressed VEGF.Materials and methods
Patients
This study was reviewed and approved by the
Kagoshima University Faculty of Medicine Commit-
tee on Human Research. We investigated retro-
spectively 22 patients with MPA who were admitted
to the Division of Respiratory Medicine, Respiratory
and Stress Care Center, Kagoshima University
Hospital from 1993 to 2005. There were 9 men
and 13 women whose mean age was 68.079.14
years old (mean7standard deviation, median ¼ 70
years old). For comparison, we also investigated
16 patients with respiratory tract infection (male:
female ¼ 7:9, mean7standard deviation ¼
67.9710.3 years old, median ¼ 68 years old,
pneumonia ¼ 10, acute bronchitis ¼ 6), 13¼ 5:8, mean7standard deviation ¼ 68.2711.1
years old, median ¼ 67 years old). The MPA
patients were diagnosed according to the defini-
tions of the 1992 Chapel Hill Consensus Confer-
ence16 based on typical history and characteristic
clinical findings and confirmed by histology. Disease
activity was assessed by using the standardized
Birmingham Vasculitis Activity Score (BVAS).17 This
clinical index is based on symptoms and signs in
nine categories: systemic signs; skin; mucous
membranes and eyes; ear, nose and throat (ENT);
chest; heart and vessels; gastrointestinal tract;
kidney; and nervous system. We excluded patients
with collagen vascular diseases including rheuma-
toid arthritis, diabetes mellitus, acute or chronic
liver disease, and immunological abnormalities that
predispose to opportunistic infection. We also
excluded the MPA patients with respiratory tract
infection and urinary tract infection. Peripheral
blood analysis, C-reactive protein (CRP), erythro-
cyte sedimentation rate (ESR), KL-6, the smoking
index (number of cigarettes smoked per day-
smoking years) and arterial oxygen pressure
(PaO2) of all patients were also determined.
All MPA patients were positive for myeloperox-
idase (MPO) anti-neutrophil cytoplasm autoantibo-
dies (ANCA). All patients with respiratory tract
infection and urinary tract infection were negative
for MPO-ANCA. All MPA patients were treated with
corticosteroids and immuno-suppressive drug (cy-
clophosphamide). In MPA, 5-year survival rate was
50% and mean survival period was 31.9728.1
months. Six patients died because of respiratory
failure, 4 patients died because of infectious
disease and one patient died because of dissemi-
nated intravascular coagulation.Measurement of VEGF
We measured serum levels of VEGF before the
patients underwent therapy of the patients with
MPA, respiratory tract infection and urinary tract
infection. In 15 patients with MPA, serum VEGF
levels were determined before therapy and 3
months after the start of therapy. We also
measured serum VEGF levels in 10 healthy volun-
teers (male:female ¼ 4:6, mean age ¼ 64.9712.3
years old). All participants gave written consent to
participate in this study.
VEGF concentrations in sera or in bronchoalveo-
lar lavage fluid (BALF) were measured in duplicate
for each sample using a commercial enzyme-
linked immunosorbent assay (ELISA) kit (R&D
Systems, Minneapolis, MN) that recognizes the
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J. Iwakawa et al.1726soluble isoforms VEGF121 and VEGF165. This assay is
sensitive to 9 pg/ml (0.2 pM) VEGF and does not
cross-react with platelet-derived growth factor or
other homologous cytokines. We also measured
interleukin-12 (IL-12) concentrations in sera using
ELISA kit that recognizes both IL-12, p40 and p70.
This assay is sensitive to 7.5 pg/ml of IL-12 and does
not cross-react with other homologous cytokines.
Optical density at 450 nm was measured on a
Titertek Multiskan MC plate reader (Flow Labora-
tories, Helsinki, Finland), and VEGF or IL-12
concentration was determined by linear regression
from a standard curve using GraphPad software
(San Diego, CA) for analysis.
Composite physiologic index
To evaluate the morphologic severity of pulmonary
lesion of MPA patients, we employed composite
physiologic index (CPI) which was introduced by
Wells et al.18 The formula for the CPI was as
follows: CPI ¼ 91.0 (0.65percent predicted dif-
fusing capacity for carbon monoxide [DLCO])
(0.53 percent predicted FVC)+(0.34percent
predicted FEV1).
Radiographic analysis
We examined the affected pulmonary segments on
high-resolution computed tomography (HRCT) to
evaluate the distribution of the lesion in patients
with MPA. The thickness of each slice was 1 cm and
30 slices were examined in total. The radiographic
findings of each subject were evaluated indepen-
dently by two investigators (a pulmonologist and a
radiologist) who have been blinded to the clinical
data. Disagreements of two CT readers were
reviewed jointly and resolved with consensus
evaluation.
BALF analysis
A bronchofibrescope (Olympus BF type p20, Olym-
pus Co., Tokyo, Japan) was wedged into the right B4
segment of the lung in order to collect BALF cells
from 11 MPA patients. Four 40-ml aliquots of sterile
physiological saline were instilled at 37 1C, and
recovered by gentle suction. The recovered fluid
was immediately filtered through sterilized gauze
and the lavage fluid was centrifuged in a cytometer
(KN-70, Kubota Ltd., Tokyo, Japan) at 44g for 5min
and stained with May–Giemsa stain in order to
identify cell populations. The supernatants were
stored at 20 1C for the measurement of VEGF. Five
hundred cells, excluding epithelial cells, wereidentified per slide in order to establish differential
cell counts, and the counts were expressed in
percentages. Concurrently, 1 105 cells were sus-
pended in 50 ml of cold PBS containing 0.1% sodium
azide, 10 ng/ml BSA and 20 mg/ml of human IgG and
incubated for 10min on ice. The cells were then
incubated for an additional 15min on ice with FITC-
conjugated CD3 or CD18 monoclonal antibody
(Becton Dickinson Co., Mountain View, CA, USA) in
combination with mouse monoclonal anti-human
CD25 or CD11b antibody (Becton Dickinson Co.).
The cells were washed with PBS, and incubated
with biotin-conjugated goat anti-mouse IgG anti-
body for 15min on ice. Cells were again washed
with PBS, and incubated with PE-conjugated
streptavidin for 15min on ice. At the end of the
incubation period, 7AAD (PharMingen, San Diego,
CA, USA) was added to each tube. The cells were
washed with PBS, and subsequently analyzed by
flow cytometry using a FACScan (Becton Dickinson).
Dead cells, identified by the 7AAD incorporation,
were gated out. Results were processed using the
CellQuest software (Becton Dickson) as described
previously.19
Intracellular staining for VEGF of BALF cells
We utilized an intracellular staining technique for
VEGF in BALF cells as described previously.20 BALF
cells from 11 MPA patients were collected as
described above. After washing with phosphate-
buffered saline (PBS), BALF cells were separated to
mononuclear cells and granulocytes using HISTOPA-
QUE 1077 and 1119 (Sigma-Aldrich, St. Louis, MO,
USA) according to the manufacturer’s protocol.
Granulocytes were stained with PE-conjugated
anti-CD11b (Becton Dickinson Co., Mountain View,
CA, USA) and mononuclear cells were stained with
CD25 monoclonal antibody (Becton Dickinson Co.).
Cells were washed with PBS, resuspended in PBS
containing 4% paraformaldehyde and then incu-
bated at 41 for 20min. After washing with PBS, cells
were resuspended in PBS containing 1% saponin and
incubated for 1 h at 4 1C with antibody for VEGF
(goat polyclonal immunoglobulin IgG; A-20, Santa
Cruz, CA, USA). Cells were rewashed with PBS
containing 1% saponin and then incubated with
fluorescein isothiocyanate (FITC)-conjugated anti-
goat IgG antibody (Cedarlane, Ontario, Canada).
After incubation, the cells were washed in PBS
containing 1% saponin, resuspended in PBS and
subsequently analyzed by flow cytometry using a
FACScan (Becton Dickinson). Dead cells, deter-
mined by the incorporation of 7AAD (Becton
Dickinson), were gated out. Results were processed
using the CellQuest software (Becton Dickson).
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Two MPA patients received lung biopsy via video-
associated thoracoscopic surgery. Both biopsied
regions showed ground-glass attenuation with con-
solidation on chest HRCT. Immunohistochemical
staining for VEGF was performed using a rabbit
polyclonal antibody (Santa Cruz, CA) employing the
DAB method using the biopsied lung samples of
these patients as described previously.13 Briefly,
4 mm-thick sections were dewaxed and rehydrated.
For optimal antigen retrieval, sections were pres-
sure cooked in 0.01M citrate buffer (pH 6.0) for
90 s. Endogenous peroxidase activity was blocked
using a 3% hydrogen peroxide solution in methanol
for 10min. After washing, sections were incubated
with primary antibody solution for 2 h at room
temperature using a 1:150 concentration working
dilution of the antibody. Negative control slides
were incubated with rabbit polyclonal antibody
(Super Sensitive Rabbit; Biogenex). After washing,
secondary biotynated anti-immunoglobulin anti-
body (Biogenex) was added, and the mixture was
incubated for 30min at room temperature. The
sections were again washed and streptavidin con-
jugated to horseradish peroxidase (Biogenex) was
incubated for 30min and then rinsed off with
deionized water. DAB substrate solution was then
added, and the mixture was incubated for 10min. A
brown color reaction represented a positive result.
Statistical analysis
We used one-way factorial analysis of variance
(ANOVA) with the Bonferroni–Dunn test, Whitney–
Mann test and Wilcoxon signed-rank test. For
statistical analysis, Stat view and MedCalc softwareTable 1 Clinical features of MPA patients on admission.
Age (years old) 68.079.14 (70)
Male:female 9:13
Symptoms
Fever (+) 22/22
Weight loss (+) 2/22
Cough (+) 18/22
Sputum (+) 5/22
Dyspnea (+) 14/22
Arthralgia (+) 6/22
Myalgia (+) 4/22
Dermatitis (+) 3/22
Neuropathy (+) 8/22
Median value in parenthesis, WBC: white blood cell, Neu.: neu
CRP: C-reactive protein, ESR: erythrocyte sedimentation rate,
cytoplasmic antibody.were used. A P-value below 0.05 was considered
significant. Most values were expressed as
mean7standard deviation (SD).Results
Table 1 shows the clinical features of MPA patients.
All MPA patients complained fever and hematuria.
Four patients did not complain any respiratory
symptoms but had arthralgia or dermatitis. Eigh-
teen patients complained cough and most cases
were not productive. Table 2 shows the chest HRCT
findings of MPA patients. Eighteen patients had
mixed radiographic findings and all of them
complained respiratory symptoms. The most fre-
quent chest HRCT finding was ‘‘Traction bronchiec-
tasis’’ and the next was ‘‘Ground-glass
attenuation’’. Fifty percent of the patients showed
‘‘Honeycombing’’. Fourteen patients had mixed
radiographic findings and these patients com-
plained dyspnea. In BALF analysis, total cell count
was 1.7570.88 105/ml, the number of macro-
phages was 1.2470.23 105/ml (71.276.24%),
lymphocytes was 0.2370.07 105/ml (13.17
5.1%), neutrophils was 0.2570.04 105/ml (14.47
4.46%), and eosinophils was 0.0270.01 105/ml
(1.3670.51%). The percentage of CD25+/CD3+
cells was 44.4713.6% and the percentage of
CD11b+/CD18+ cells was 52.9710.4%.
The serum VEGF levels in patients with MPA were
significantly higher than in patients with respira-
tory tract infection (pneumonia and acute bron-
chitis), urinary tract infection or healthy volunteers
(MPA patients: mean7SD ¼ 1104.57684.3 pg/ml;
patients with respiratory tract infection: mean7
SD ¼ 391.27133.8 pg/ml; patients with urinary tractLaboratory data
WBC 1091573167/ml
Neu. 7979.22%
Lym. 1477.02%
Hb. 1171.85g/dl
CRP 10.274.46mg/dl
ESR 63723.7mm/h
KL-6 6077394.1U/ml
Cr. 1.0070.58mg/dl
Hematuria (+) 22/22
Albuminuria (+) 14/22
MPO-ANCA 3387512.2EU
trophil, Lym.: Lymphocytes, Hb.: hemoglobin, Plt.: platelet,
Cr.: creatinine, MPO-ANCA: myeloperoxidase-antineutrophil
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Table 2 Findings on chest CT in 22 MPA patients.
Finding No. of
patients (%)
Ground-glass attenuation 14 (63.6)
Consolidation 9 (40.9)
Thickening of bronchovascular
bundle
9 (40.9)
Nodules 6 (27.3)
Honeycombing 11 (50)
Traction bronchiectasis 19 (86.4)
Pleural effusion 7 (31.8)
Lymph node swelling 3 (13.6)
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Figure 1 Serum VEGF levels in each patient group. The
serum VEGF level in MPA patients was significantly higher
than those in patients with respiratory tract infection,
urinary tract infection and healthy volunteers
(a, *Po0:01, Bonferroni–Dunn test with one-way factorial
ANOVA, MPA: microscopic polyangiitis, RTI: respiratory
tract infection, UTI: urinary tract infection, HV: healthy
volunteer). The serum VEGF levels significantly de-
creased 3 months after the start of therapy (b, Po0:05,
Whitney–Mann test).
J. Iwakawa et al.1728infection: mean7SD ¼ 364.17118.9 pg/ml; healthy
volunteers: mean7SD ¼ 98.3743.3 pg/ml; Fig. 1a).
The sensitivity of VEGF levels to distinguish MPA
from respiratory tract infection or urinary tract
infection was 81.8%, and specificity was 93.5%
(cutoff value ¼ 527.5 pg/ml, positive predicted
value ¼ 90%, negative predicted value ¼ 87.9%).
The serum VEGF levels of 15 patients with
MPA significantly decreased 3 month after the
start of therapy (before ¼ 1084.77345.9 pg/ml,
after ¼ 339.17156.9 pg/ml, Po0:05, Whitney–
Mann test, Fig. 1b). Three months after the start
of therapy, the clinical symptoms and serum
inflammatory markers such as CRP of MPA patients
were improved successfully by the treatment. The
serum VEGF levels in MPA patients with poor
prognosis (died within 5 years, 1491.37705.9 pg/
ml) was significantly higher than those with good
prognosis (survived more than 5 years,
786.17511.9 pg/ml, Po0:05, Whitney–Mann test).
The sensitivity of VEGF levels to distinguish MPA
patient who died within 5 years from MPA patients
who survived more than 5 years was 90.9%, and
specificity was 81.8% (cut off value ¼ 802.5 pg/ml,
positive predicted value ¼ 83.3%, negative pre-
dicted value ¼ 90%). The serum VEGF levels did
not show significant correlation with MPO-
ANCA level (r ¼ 0:136, P ¼ 0:5), platelet counts
(r ¼ 0:323, P ¼ 0:1), CRP level (r ¼ 0:111, P ¼ 0:9),
ESR (r ¼ 0:141, P ¼ 0:8), KL-6 (r ¼ 0:071, P ¼ 0:7),
smoking index (r ¼ 0:139, P ¼ 0:3) and PaO2 level
(r ¼ 0:338, P ¼ 0:08). Regarding IL-12, serum IL-
12 levels in healthy volunteers was significantly
lower than those of other three groups (Po0:01,
Bonferroni–Dunn with one way factorial ANOVA,
MPA patients: mean7SD ¼ 194.57114.8 pg/ml; pa-
tients with respiratory tract infection: mean7
SD ¼ 206.17106.7 pg/ml; patients with urinary tract
infection: mean7SD ¼ 182.37112.7 pg/ml; healthy
volunteers: mean7SD ¼ 57.9735.4 pg/ml). How-
ever, there was no significant difference of serum
IL-12 levels among the MPA patients, patientswith respiratory tract infection and patients with
urinary tract infection. Also, there was no signifi-
cant difference of serum IL-12 levels between the
MPA patient with poor prognosis (MPA patients who
died within 5 years, 211.37121.3 pg/ml) and the
MPA patients with good prognosis (MPA patients who
survived more than 5 years, 177.87111.1 pg/ml).
The serum IL-12 levels did not show significant
correlation with CPI (r ¼ 0:193, P ¼ 0:395).
Serum VEGF levels in MPA patients showed
significant positive correlation with CPI (r ¼ 0:801,
Po0:0001, Wilcoxon signed-rank test, Fig. 2a)
and BVAS (r ¼ 0:583, Po0:05, Wilcoxon signed-
rank test, Fig. 2b). Serum MPO-ANCA levels did not
show any significant correlation with visual score
(r ¼ 0:109, P ¼ 0:12) and BVAS (r ¼ 0:139, P ¼ 0:1).
In MPA, serum VEGF levels of the patients who
showed ground-glass attenuation (GGA) in chest
CT were significantly higher than the patients
without ground-glass attenuation (GGA+ ¼
1368.77705.9 pg/ml, GGA ¼ 723.17402.5 pg/ml,
Po0:05, Whitney–Mann test, Fig. 3a). Also,
serum VEGF levels of the patients who showed
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Figure 2 Correlation between serum VEGF level and
visual score or BVAS. The serum VEGF levels in MPA
patients showed significant correlation with visual score
(a, r ¼ 0:809, Po0:001, Wilcoxon signed-rank test) and
BVAS (b, r ¼ 0:587, Po0:01, Wilcoxon signed-rank test).
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Figure 3 Comparison of serum VEGF level in each chest
CT appearance. The serum VEGF levels in patients with
ground-glass attenuation (a, Po0:05, Whitney–Mann
test, GGA: ground-glass attenuation) or consolidation
(b, Po0:01, Whitney–Mann test) were significantly higher
than those without these shadows. There was no
significant difference of serum VEGF levels between the
patients with honeycombing and those without honey-
combing (c).
VEGF in MPA 1729consolidation in chest CT were significantly higher
than the patients without consolidation (consolida-
tion+ ¼ 1523.67681.3 pg/ml, consolidation ¼
685.57364.7 pg/ml, Po0:01, Whitney–Mann test,
Fig. 3b). Concerning the other chest CT appearance
such as honeycombing (Fig. 3c), there was no
significant difference of serum VEGF levels be-
tween the patients with or without chest CT
appearance.
Concerning the intracellular staining for VEGF,
CD11b+ pulmonary granulocytes (Fig. 4a), not
CD25+ pulmonary mononuclear cells (Fig. 4b), were
stained positive for VEGF. The VEGF+/CD11b+
granulocyte percentage showed significant positive
correlation with CD11b+/CD18+ BALF cell percen-
tage (Fig. 4c). The VEGF+/CD11b+ granulocyte
percentage also showed significant positive corre-
lation with CPI (Fig. 4d). The CD11b+/CD18+ BALF
cell percentage showed significant positive correla-
tion with serum VEGF levels (r ¼ 0:721, Po0:05).
The VEGF+/CD11b+ BALF cell percentage showed
positive correlation with serum VEGF levels, how-
ever it was not statistical significant (r ¼ 0:511,
P ¼ 0:052). The VEGF levels in BALF showed
significant positive correlation with CPI (r ¼
0:812, Po0:01) and with VEGF+/CD11b+ BALF cell
percentage (r ¼ 0:629, Po0:05).
In immunohistochemical analysis, infiltrating in-
flammatory cells, alveolar macrophages and alveo-lar epithelial cells were stained positive for VEGF
(Fig. 5).Discussion
In this study, the serum VEGF levels of MPA patients
with poor prognosis were significantly higher than
those with good prognosis. Five-year survival rate
in our study was 50% and this is almost same with
previous reports.3,21 The sensitivity and specificity
of VEGF levels for the prediction of poor prognosis
were 90.9% and 81.8%, respectively (cut off
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Figure 4 Analysis of VEGF expression in bronchoalveolar
lavage fluid (BALF) cells. CD11b+ pulmonary granulocytes
expressed high amount of VEGF (a, representative data in
11 cases), however CD25+ pulmonary mononuclear cells
expressed little amount of VEGF (b, representative data
in 11 cases). The CD11b+/CD18+ percentage showed
significant positive correlation with VEGF+/CD11b+ BALF
cells (c, r ¼ 0:856, Po0:001, Wilcoxon signed-rank test)
and visual score (d, r ¼ 0:813, Po0:01, Wilcoxon signed-
rank test).
J. Iwakawa et al.1730value ¼ 802.5 pg/ml). VEGF may be a useful
screening marker to predict poor prognosis of
MPA, as a negative result greatly reduces the death
within 5 years. However, a cautious follow up for
the MPA patients with low serum VEGF levels is also
necessary as the specificity is relatively low. In our
study, the serum VEGF levels showed significant
positive correlation with disease activity. Hypoxia22
and smoking23 that can affect serum VEGF levels
did not show significant correlation with serum
VEGF levels. There has been several reports
showing the clinical value of VEGF in monitoring
disease activity in vasculitis including MPA.24–26 Our
result is compatible with previous reports and wepropose that serum VEGF might become one of the
serum markers that reflect disease activity of MPA.
We also showed that serum VEGF levels in MPA
patients were significantly higher than those in
respiratory tract infection and urinary tract infec-
tion. However, there some overlap between the
VEGF levels of the MPA and respiratory tract
infection or urinary tract infection patients in our
study. This fact indicates that measurement of
VEGF alone cannot be a definitive marker to
distinguish MPA from respiratory or urinary traction
infection and suggest the necessity of measurement
of standard markers such as MPO-ANCA for the
accurate diagnosis and for the prediction of exact
prognosis.
The MPA cases investigated in this study showed
various chest HRCT appearance. In MPA, it was
traditionally considered that the predominant
pulmonary symptom is hemoptysis and this symp-
tom reflects the alveolar hemorrhage caused by
capillaritis.1 Therefore, the traditionally reported
chest radiographic feature was patchy, bilateral
airspace opacities caused by alveolar hemor-
rhage.1,6 However, resent studies found that MPA
reveals a variety of pulmonary findings, including
ground-glass attenuation, consolidation, thickening
of bronchovascular bundles, and honeycombing.4,5
Especially, Ando et al.4 reported that the chest
HRCT findings consisted of ground-glass attenuation
in 94% of the patients, consolidation in 78%, and
thickening of bronchovascular bundles in 51%. In
our study, the chest HRCT findings consisted of
traction bronchiectasis in 86.4%, ground-glass
attenuation in 63.6%, and honeycombing in 50% of
the MPA patients. Thus, the chest HRCTappearance
of MPA is variable and, therefore, we believe that
the patients with pulmonary shadows as described
above should be examined about the existence
of ANCA.
In our study, the serum VEGF level was signifi-
cantly higher in patients with ground-glass attenua-
tion or consolidation than those without these
shadows. In addition, serum VEGF levels showed
significant positive correlation with the affected
pulmonary area and disease activity. In MPA, it was
reported that the pathological feature of ground-
glass attenuation is chronic inflammation with
vasculitis and the pathological feature of consoli-
dation is alveolar hemorrhage.4 Taken together, it
might be possible that these shadows reveal the
existence of active pulmonary lesion in MPA
patients. Regarding other shadows, Eschun et al.
reported that pulmonary fibrosis shadow including
honeycombing and traction bronchiectasis occur as
a pulmonary manifestation of MPA and suggested
that repeated episodes of alveolar hemorrhage
ARTICLE IN PRESS
Figure 5 Immunohistochemical analysis for VEGF. Infiltrating inflammatory cells, alveolar macrophages and alveolar
epithelial cells were stained positive for VEGF (a and c: stained with anti-VEGF antibody, b and d: negative control.
 400 original magnification).
VEGF in MPA 1731could be the forerunner of interstitial fibrosis in
MPA.6 In our study, there was no significant
difference of serum VEGF levels between the
patients with traction bronchiectasis or honey-
combing and without these shadows. It might be
possible that these shadows (traction bronchiecta-
sis or honeycombing) were the result of repeated
pulmonary capillaritis and, therefore, no significant
difference of the serum VEGF level was seen. We
propose the necessity of further studies to clarify
the features of chest radiographic appearance
of MPA.
Our study showed that CD11b+ pulmonary gran-
ulocytes expressed VEGF. The VEGF+/CD11b+ gran-
ulocyte percentage showed significant positive
correlation with CD11b+/CD18+ BALF cell percen-
tage. The CD18 (b2-integrin) is heterodimeric
integral membrane glycoprotein expressed mainly
on neutrophils and consist of a common CD18
b-chain that can associate with one of four a-chains
termed CD11a (LFA-1), CD11b (Mac-1), CD11c
(p150), and CD11d.27 In experiments with blocking
antibodies specific for b2-integrin a-chains, it was
determined that neutrophil adhesion to epithelial
cells is mediated exclusively by CD11b and CD18.28
CD11b (Mac-1) is the receptor for complement 3bi29
and it contributes to the neutrophil rolling on
endothelium and facilitating phagocytosis of opso-nized particles in neutrophils.30 Therefore, we
think CD11b+ pulmonary granulocytes are activated
pulmonary neutrophils that can adhere and roll on
endothelium. Proteinase-3 and MPO-ANCA can
activate neutrophils via Fc-gamma receptor IIa-
mediated mechanism.31 Neutrophils are able to
express VEGF32,33 and, especially, neutrophil-de-
rived VEGF is reported to play a role in regulating
early vascular responses in Kawasaki disease.33
Tumor necrosis factor alpha, which plays an
important role in MPA,34 can up-regulate the
expression of VGEF.35 In contrast, CD25+ pulmonary
mononuclear cells, which are considered as acti-
vated lymphocytes,36 did not express VEGF in our
study. CD11b+ pulmonary granulocytes showed
significant positive correlation with serum VEGF
levels. BALF VEGF levels showed significant corre-
lation with VEGF+/CD11b+ cell percentage. In
immunohistochemical analysis, small infiltrating
inflammatory cells were stained positive for VEGF.
Taken together, we think that pulmonary activated
neutrophils might be one of the cellular sources of
VEGF in MPA.
In our study, serum IL-12 levels, one of the anti-
angiogenic cytokines,37,38 did not show any correla-
tion with MPA prognosis and severity of pulmonary
lesion in our study. Furthermore, in immunohisto-
chemical analysis, not only inflammatory cells but
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J. Iwakawa et al.1732also alveolar macrophages and alveolar epithelial
cells were stained positive for VEGF. Alveolar
macrophages13 and alveolar epithelial cells39,40
are capable to produce VEGF. The serum VEGF
levels of MPA patients decreased after the treat-
ment with corticosteroids and cyclophosphamide.
We think these treatments might contribute to the
decrease of serum VEGF because corticosteroids
can inhibit VEGF production from pulmonary
cells41,42 and cyclophosphamide can also inhibit
VEGF production in vivo.43 Indeed, VEGF induce
vascular endothelial cell proliferation and cause
intense angiogenesis44 and increase vascular per-
meability.7,8 In our study, BALF VEGF levels showed
significant correlation with CPI. VEGF production in
the pulmonary lesion might contribute to the
development of pulmonary involvement in MPA.
Further studies addressing this point might be
important to clarify the pathogenesis of pulmonary
involvement in MPA.Acknowledgement
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